Maternal drug use in early pregnancy and infant cardiovascular defect
Maternal drug use in early pregnancy and infant cardiovascular defect
复制标题
DOI：
10.1016/s0890-6238(03)00012-1
复制
发表时间：
2003-05-01
影响因子：
3.3
通讯作者：
Olausson, PO
中科院分区：
文献类型：
--
作者：
Källén, BAJ;Olausson, PO
本文的目的是确定母亲的药物使用可能与增加后代心脏缺陷的风险有关。进行了一项病例对照研究，从三个瑞典健康登记册（n = 5015）中确定病例（无已知染色体异常的心血管缺陷），对照组为1995年7月1日至2001年7月1日期间在瑞典出生的所有婴儿（n = 577,730）。在妊娠早期通过访谈获得药物暴露信息。鼻腔制剂中胰岛素、抗高血压药、生育药、红霉素、萘普生、抗惊厥药、呋喃妥因、氯米帕明和布地奈德的使用与婴儿心血管缺陷之间存在关联。其中一些关联可能是由于潜在疾病或主诉引起的混淆，一些可能是由于多次试验，一些可能是真正的药物作用。需要进一步的研究来证实或否定这些关联。(C) 2003爱思唯尔科学有限公司版权所有。
The purpose of the paper is to identify maternal drug use that may be associated with an increased risk for cardiac defects in the offspring. A case-control study was performed with cases (cardiovascular defects without known chromosome anomalies) being identified from three Swedish health registers (n = 5015) and controls being all infants born in Sweden during the period 1 July 1995-2001 (n = 577,730). Information on drug exposure was obtained by interview in early pregnancy. Associations between maternal drug use and infant cardiovascular defect were identified for insulin, antihypertensives, fertility drugs, erythromycin, naproxen, anticonvulsants, nitrofurantoin, clomipramine, and budesonide in nasal preparations. Some of these associations are probably due to confounding from underlying disease or complaint, some may be due to multiple testing, some may be true drug effects. Further studies are needed to verify or reject these associations. (C) 2003 Elsevier Science Inc. All rights reserved.